New research has shown that Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of care in patients with type 2 diabetes at high risk of CV events.
Jardiance was developed, and is now marketed, under a collaboration between Germany family-owned Boehringer Ingelheim and partner US drug major Eli Lilly (NYSE: LLY). Lilly’s shares rose 6.3% to $89.74 on above-average volume, having hit $90.46 in intraday trading, and reaching a near 15-year high, according to Dow Jones.
The EMPA-REG OUTCOME trial was conducted to meet regulatory demands that makers of diabetes drugs show their products do not increase CV risk.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze